Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1140]

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide...

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center...

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )

Time to metastasis after prostatectomy should not be used as a prognostic...

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as...

Prof Amit Bahl - University Hospitals Bristol, Bristol, UK

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option ( Prof Amit Bahl - University Hospitals Bristol, Bristol, UK )

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell...

Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma ( Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA )

UGN-102 shows better results after 12 months of treatment for low-grade...

Dr Sandip Prasad - Garden State Urology, Morristown, USA

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC ( Dr Sandip Prasad - Garden State Urology, Morristown, USA )

Mobile prostate cancer screening clinic can help address barriers to serving...

Dr Masood Moghul - The Royal Marsden Institute of Cancer Research, London, UK

Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities ( Dr Masood Moghul - The Royal Marsden Institute of Cancer Research, London, UK )

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in...

Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC ( Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA )

CaboNivo shows sustained long-term benefits for survival and tumour progression...

Prof Camillo Porta - University of Bari, Bari, Italy,

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta - University of Bari, Bari, Italy, )

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide...

Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone ( Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA )

Enfortumab vedotin in combination with pembrolizumab shows improved survival...

Prof Thomas Powles - Barts Cancer Institute, London, England

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC ( Prof Thomas Powles - Barts Cancer Institute, London, England )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Prostate cancer

Dr Alison Tree - Institute of Cancer Research, London, UK

Prostate cancer ( Dr Alison Tree - Institute of Cancer Research, London, UK )

More from ecancer